MX9307044A - Polipetidos de afinidad modificada de anticuerpos que se unen a quelatos metalicos. - Google Patents

Polipetidos de afinidad modificada de anticuerpos que se unen a quelatos metalicos.

Info

Publication number
MX9307044A
MX9307044A MX9307044A MX9307044A MX9307044A MX 9307044 A MX9307044 A MX 9307044A MX 9307044 A MX9307044 A MX 9307044A MX 9307044 A MX9307044 A MX 9307044A MX 9307044 A MX9307044 A MX 9307044A
Authority
MX
Mexico
Prior art keywords
polypethydes
antibodies
modified affinity
affinity
bind metallic
Prior art date
Application number
MX9307044A
Other languages
English (en)
Inventor
Patricia Marie Ahrweiler
Margaret Dow Moore
Original Assignee
Hybritech Incorporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Incorporation filed Critical Hybritech Incorporation
Publication of MX9307044A publication Critical patent/MX9307044A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6887—Antibody-chelate conjugates using chelates for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Está invención aporta un polipéptido que tiene una secuencia de aminoácidos que incluye una secuencia de una región determinante de complementariedad (CDR) de un anticuerpo nativo que tiene una sustitución aminoacidica, teniendo el polipétido afinidad por la unión de un quelato metálico de EDTA a un análogo de EDTA que es aproximadamente igual o modificada de la afinidad de unión del anticuerpo nativo.
MX9307044A 1992-11-12 1993-11-11 Polipetidos de afinidad modificada de anticuerpos que se unen a quelatos metalicos. MX9307044A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97523092A 1992-11-12 1992-11-12

Publications (1)

Publication Number Publication Date
MX9307044A true MX9307044A (es) 1994-05-31

Family

ID=25522807

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9307044A MX9307044A (es) 1992-11-12 1993-11-11 Polipetidos de afinidad modificada de anticuerpos que se unen a quelatos metalicos.

Country Status (7)

Country Link
EP (1) EP0623675A1 (es)
JP (1) JPH06343489A (es)
AU (1) AU5060293A (es)
CA (1) CA2102848A1 (es)
HU (1) HUT67186A (es)
MX (1) MX9307044A (es)
ZA (1) ZA938243B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0759291A1 (en) 1995-08-14 1997-02-26 The Procter & Gamble Company Cleansing preparation and articles comprising a cleansing preparation
AUPO066096A0 (en) * 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
US6071490A (en) * 1998-05-07 2000-06-06 Immunomedics, Inc. Position emission tomography using gallium-68 chelates
ES2216510T3 (es) * 1998-05-07 2004-10-16 Immunomedics, Inc. Tomografia de emision de positrones utilizando quelatos de galio 68.
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US7833528B2 (en) 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7387772B1 (en) 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US7052872B1 (en) 1999-06-22 2006-05-30 Immunomedics, Inc. Bi-specific antibodies for pre-targeting diagnosis and therapy
JP4113670B2 (ja) * 1998-06-22 2008-07-09 イムノメディクス， インコーポレイテッド プレターゲッティング診断およびプレターゲッティング治療のための二重特異性抗体の使用
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
CA2632822C (en) 2005-12-12 2018-08-28 Ruth Greferath A beta 1-42 specific monoclonal antibodies with therapeutic properties
AR062065A1 (es) 2006-07-14 2008-10-15 Ac Immune Sa Anticuerpo humanizado
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
BRPI0812484A2 (pt) * 2007-06-12 2018-06-05 Ac Immune Sa anticorpo monoclonal, regiões variáveis de cadeia leve e de cadeia pesada, cdr isolada, polinucleotídeo, composição terapêutica, métodos para tratar doenças e distúrbios, para produzir um anticorpo, para tratar ou aliviar os efeitos de doenças e distúrbios, para reduzir a carga de placas no cérebro de um indivíduo, para reduzir a quantidade de placas no cérebro de um indivíduo, para diminuir a quantidade total de abeta solúvel no cérebro de um indivíduo, para reter ou aumentar a capacidade de memória cognitiva em um indivíduo, de diagnose de ou para diagnosticar uma predisposição para uma doença associada com amilóide ou condição em um paciente, para determinar a extensão de carga de placa amiloidogênica em um tecido de um indivíduo, para monitorar doença residual mínima em um indivíduo e para prever responsividade de um indivíduo, linhagem de células, kit de teste, epítopo abeta
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
CA2806909C (en) 2010-07-30 2019-12-17 Ac Immune S.A. Safe and functional humanized antibodies
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722892A (en) * 1984-08-31 1988-02-02 Meares Claude F Monoclonal antibodies against metal chelates
ATE107276T1 (de) * 1988-02-03 1994-07-15 Hybritech Inc Modifizierte haptene, nützlich als bildformendes agens und als arzneimittel.
IL89491A0 (en) * 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
IL99552A0 (en) * 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof

Also Published As

Publication number Publication date
AU5060293A (en) 1994-05-26
CA2102848A1 (en) 1994-05-13
HU9303200D0 (en) 1994-01-28
ZA938243B (en) 1995-05-04
EP0623675A1 (en) 1994-11-09
HUT67186A (en) 1995-02-28
JPH06343489A (ja) 1994-12-20

Similar Documents

Publication Publication Date Title
MX9307044A (es) Polipetidos de afinidad modificada de anticuerpos que se unen a quelatos metalicos.
DE3584443D1 (de) Monoklonale antikoerper gegen metallchelate.
PE20090046A1 (es) Anticuerpo recombinante humanizado anti-interleuquina 10
DK0937140T3 (da) Antistofmolekyler, som interagerer specifikt med et målmolekyles aktive sted eller klöft
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
ATE172743T1 (de) Nachweis von kollagenabbau -i(in vivo)
CY1118709T1 (el) Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf
CY1110877T1 (el) Αλλαγη των συγγενειων συνδεσης me fcrn ή των ημιζωων ορου αντισωματων με μεταλλαξιγενεση
DE69527975D1 (de) Humanisierte antikörper gegen cd38
ATE473754T1 (de) Verfahren zur manipulation der zelldifferenzierung
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
PT804237E (pt) Anticorpos humanizados contra a molecula de adesao leucocitaria vla-4
DK0724456T3 (da) CD40-Antistoffer
ATE421976T1 (de) Fab fragmentbibliotheken und verfahren für deren verwendung
ES2173130T3 (es) Metodo de fijacion de material al peptido beta-amiloide.
RU2017146220A (ru) Конъюгированные через cys80 иммуноглобулины
ATE182366T1 (de) Immunoassays für und monoklonale antikörper gegen prothrombin-aktivierende peptide und ihre abbauprodukte
ATE180489T1 (de) Für leberzellkarzinom spezifisches onkogen
NZ535908A (en) HIV regulatory and auxilliary peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
EP0725081A4 (en) MONOCLONAL ANTIBODIES AGAINST MxA OF Mx PROTEIN OF MAN
ES2114547T3 (es) Anticuerpos monoclonales contra el virus de la hepatitis c.
CA2137280A1 (fr) Clonage du gene codant pour la proteine gp28.5 de toxoplasma gondii; fragments peptidiques de cette proteine et leurs applications
ATE543906T1 (de) Antigen von streptococcus aus der b-gruppe
DE69428041D1 (de) Inhibierung von Leukozytenadhäsion
ATE122895T1 (de) Monoklonale antikörper gegen den interleukin 2- rezeptor.